Intrinsic transcriptional heterogeneity in neuroblastoma guides mechanistic and therapeutic insights.

Autor: Shendy NAM; Division of Molecular Oncology, Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA., Zimmerman MW; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Abraham BJ; Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA., Durbin AD; Division of Molecular Oncology, Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA. Electronic address: adam.durbin@stjude.org.
Jazyk: angličtina
Zdroj: Cell reports. Medicine [Cell Rep Med] 2022 May 17; Vol. 3 (5), pp. 100632.
DOI: 10.1016/j.xcrm.2022.100632
Abstrakt: Cell state is controlled by master transcription factors (mTFs) that determine the cellular gene expression program. Cancer cells acquire dysregulated gene expression programs by mutational and non-mutational processes. Intratumoral heterogeneity can result from cells displaying distinct mTF-regulated cell states, which co-exist within the tumor. One archetypal tumor associated with transcriptionally regulated heterogeneity is high-risk neuroblastoma (NB). Patients with NB have poor overall survival despite intensive therapies, and relapsed patients are commonly refractory to treatment. The cellular populations that comprise NB are marked by different cohorts of mTFs and differential sensitivity to conventional therapies. Recent studies have highlighted mechanisms by which NB cells dynamically shift the cell state with treatment, revealing new opportunities to control the cellular response to treatment by manipulating cell-state-defining transcriptional programs. Here, we review recent advances in understanding transcriptionally defined cancer heterogeneity. We offer challenges to the field to encourage translation of basic science into clinical benefit.
(Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE